Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice

Introduction and objectives: Heart failure (HF) is a clinical syndrome associated with substantial morbidity, mortality, and healthcare costs. Dapagliflozin has proven efficacy in reducing the risk of death and hospitalization in HF patients, regardless of left ventricular ejection fraction (LVEF)....

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Dulce Brito, Cândida Fonseca, Fátima Franco, Vanessa Lopes, Sara Gonçalves, Rui Baptista, Joana Sequeira, Irene Marques, Rita Rego, Joana Pimenta, José Silva-Cardoso, Margarida Lopes, Mário Almeida
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2024-12-01
Sarja:	Revista Portuguesa de Cardiologia
Aiheet:	Insuficiência cardíaca iSGLT2 Dapagliflozina Custos de saúde Encargos económicos Hospitalização por IC
Linkit:	http://www.sciencedirect.com/science/article/pii/S0870255124002269
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!